NF1 and neoplasm: Moreover, JQ1 treatment has shown synergistic activity with trametinib in malignant peripheral nerve sheath tumors (MPNSTs) driven by neurofibromin 1 (NF1) mutation and polycomb repressive complex 2 (PRC2) loss [47], suggesting further utility of this therapeutic approach in other tumor types.